Literature DB >> 16350384

Use of bivalirudin as an anticoagulant during cardiopulmonary bypass.

James J Veale1, Harry M McCarthy, George Palmer, Cornelius M Dyke.   

Abstract

Bivalirudin is a short-acting direct thrombin inhibitor that has been used in cardiac surgical patients with heparin-induced thrombocytopenia (HIT) or suspected HIT. Although no direct thrombin inhibitor is indicated for anticoagulation during cardiac surgery in patients with heparin-induced thrombocytopenia (HIT) or suspected HIT, use of heparin-alternatives are increasing as the awareness of HIT increases. Reports of anticoagulation with bivalirudin are sporadic, however, with variable dosing and management strategies. In this report, we describe our management techniques for cardiopulmonary bypass with bivalirudin based upon our personal experience. Although the reported clinical experience with bivalirudin in cardiac surgery is reviewed, operative techniques for the perfusionist/surgeon team are discussed in detail. We recognize that the use of bivalirudin during cardiopulmonary bypass is evolving and modifications of technique will undoubtedly occur as further data and experience accumulate.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16350384      PMCID: PMC4680789     

Source DB:  PubMed          Journal:  J Extra Corpor Technol        ISSN: 0022-1058


  15 in total

1.  Successful use of bivalirudin for cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia.

Authors:  George Gordon; Hassan Rastegar; Roman Schumann; Judith Deiss-Shrem; William Denman
Journal:  J Cardiothorac Vasc Anesth       Date:  2003-10       Impact factor: 2.628

2.  Effectiveness of bivalirudin as a replacement for heparin during cardiopulmonary bypass in patients undergoing coronary artery bypass grafting.

Authors:  Andreas Koster; Bruce Spiess; Derek P Chew; Thomas Krabatsch; Luc Tambeur; Abe DeAnda; Roland Hetzer; Hermann Kuppe; Nicholas G Smedira; A Michael Lincoff
Journal:  Am J Cardiol       Date:  2004-02-01       Impact factor: 2.778

3.  Cardiopulmonary bypass with bivalirudin in type II heparin-induced thrombocytopenia.

Authors:  Stephanie B Clayton; Jeffrey R Acsell; Arthur J Crumbley; Walter E Uber
Journal:  Ann Thorac Surg       Date:  2004-12       Impact factor: 4.330

4.  Recombinant hirudin anticoagulation for aortic valve replacement in heparin-induced thrombocytopenia.

Authors:  D Longrois; E de Maistre; N Bischoff; C Dopff; C Meistelman; M Angioï; T Lecompte
Journal:  Can J Anaesth       Date:  2000-03       Impact factor: 5.063

5.  Heparin-induced thrombocytopenia in patients treated with unfractionated heparin: prevalence of thrombosis in a 1 year follow-up.

Authors:  A V Mattioli; L Bonetti; S Sternieri; G Mattioli
Journal:  Ital Heart J       Date:  2000-01

6.  Anticoagulation with bivalirudin during cardiopulmonary bypass in cardiac surgery.

Authors:  Julio C Vasquez; Anna Vichiendilokkul; Syed Mahmood; Frank A Baciewicz
Journal:  Ann Thorac Surg       Date:  2002-12       Impact factor: 4.330

7.  Favorable outcome with bivalirudin anticoagulation during cardiopulmonary bypass.

Authors:  Zev Davis; Richard Anderson; Daniel Short; David Garber; Araldo Valgiusti
Journal:  Ann Thorac Surg       Date:  2003-01       Impact factor: 4.330

8.  Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin.

Authors:  T E Warkentin; M N Levine; J Hirsh; P Horsewood; R S Roberts; M Gent; J G Kelton
Journal:  N Engl J Med       Date:  1995-05-18       Impact factor: 91.245

9.  Bivalirudin versus heparin and protamine in off-pump coronary artery bypass surgery.

Authors:  Alan F Merry; Peter J Raudkivi; Neil G Middleton; John M McDougall; Parma Nand; Brigid P Mills; Bruce J Webber; Chris M Frampton; Harvey D White
Journal:  Ann Thorac Surg       Date:  2004-03       Impact factor: 4.330

10.  High incidence of anti-heparin/platelet factor 4 antibodies after cardiopulmonary bypass surgery.

Authors:  M Trossaërt; A Gaillard; P L Commin; J Amiral; A M Vissac; E Fressinaud
Journal:  Br J Haematol       Date:  1998-06       Impact factor: 6.998

View more
  5 in total

1.  Anticoagulant therapy during cardiopulmonary bypass.

Authors:  Maryam Yavari; Richard C Becker
Journal:  J Thromb Thrombolysis       Date:  2008-10-19       Impact factor: 2.300

2.  Bivalirudin as an Alternative Anticoagulant for Cardiopulmonary Bypass During Adult Cardiac Surgery-A Change in Practice.

Authors:  Peter Gatt; Samuel Anthony Galea; Walter Busuttil; Charles Grima; Jeffrey Muscat; Yvette Farrugia
Journal:  J Extra Corpor Technol       Date:  2017-03

3.  A modified technique for implantation of the HeartWare™ left ventricular assist device when using bivalirudin anticoagulation in patients with acute heparin-induced thrombocytopenia.

Authors:  Michiel Morshuis; Jochen Boergermann; Jan Gummert; Andreas Koster
Journal:  Interact Cardiovasc Thorac Surg       Date:  2013-04-28

Review 4.  Heparin induced thrombocytopenia with mechanical circulatory support devices: review of the literature and management considerations.

Authors:  Jonathan Bain; Alexander H Flannery; Jeremy Flynn; William Dager
Journal:  J Thromb Thrombolysis       Date:  2017-07       Impact factor: 2.300

Review 5.  The Use of Bivalirudin in Pediatric Cardiac Surgery and in the Interventional Cardiology Suite.

Authors:  Dheeraj Goswami; Matthew DiGiusto; Rajeev Wadia; Sean Barnes; Jamie Schwartz; Diana Steppan; Kristen Nelson-McMillan; Richard Ringel; Jochen Steppan
Journal:  J Cardiothorac Vasc Anesth       Date:  2020-01-21       Impact factor: 2.628

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.